CHARLES SCHWAB INVESTMENT MANAGEMENT INC - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 88 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.1%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,359,470
-22.1%
249,444
-3.0%
0.00%
Q2 2023$1,745,675
+47.9%
257,095
+9.1%
0.00%
Q1 2023$1,180,556
-3.8%
235,640
-6.3%
0.00%
Q4 2022$1,227,608
-65.7%
251,559
+1.3%
0.00%
-100.0%
Q3 2022$3,583,000
-4.4%
248,415
+0.3%
0.00%0.0%
Q2 2022$3,747,000
+34.9%
247,608
+5.9%
0.00%0.0%
Q1 2022$2,778,000
-30.0%
233,756
-4.5%
0.00%0.0%
Q4 2021$3,968,000
-42.0%
244,744
+2.1%
0.00%
-50.0%
Q3 2021$6,839,000
+0.1%
239,619
+18.6%
0.00%0.0%
Q2 2021$6,832,000
+18.6%
202,119
+6.1%
0.00%0.0%
Q1 2021$5,762,000
-34.4%
190,518
+7.3%
0.00%
-33.3%
Q4 2020$8,787,000
+32.9%
177,476
+3.0%
0.00%0.0%
Q3 2020$6,613,000
+8.6%
172,240
+22.3%
0.00%0.0%
Q2 2020$6,087,000
+93.0%
140,881
+16.6%
0.00%
+50.0%
Q1 2020$3,154,000
-14.8%
120,808
+1.9%
0.00%0.0%
Q4 2019$3,704,000
+63.0%
118,528
+36.0%
0.00%
+100.0%
Q3 2019$2,272,000
+50.5%
87,154
+32.0%
0.00%0.0%
Q2 2019$1,510,000
+61.2%
66,001
+84.7%
0.00%0.0%
Q1 2019$937,000
+23.1%
35,733
-4.4%
0.00%0.0%
Q4 2018$761,00037,3820.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Memorial Sloan Kettering Cancer Center 191,176$2,271,0002.63%
Sofinnova Investments, Inc. 2,194,278$26,068,0001.98%
MPM BioImpact LLC 443,702$5,271,0001.42%
Soleus Capital Management, L.P. 238,982$2,839,0000.37%
Lombard Odier Asset Management (Switzerland) SA 221,774$2,635,0000.21%
Artal Group S.A. 400,000$4,752,0000.20%
Polar Capital Holdings Plc 2,877,671$34,187,0000.15%
ASHFORD CAPITAL MANAGEMENT INC 106,770$1,268,0000.14%
Cormorant Asset Management, LP 150,000$1,782,0000.14%
Virtus ETF Advisers LLC 23,646$281,0000.13%
View complete list of Y-MABS THERAPEUTICS INC shareholders